{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:03:32Z","timestamp":1771437812720,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01184-w","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:35:15Z","timestamp":1769106915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-8361","authenticated-orcid":false,"given":"Dominic S.","family":"Br\u00e4m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Gotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klervi","family":"Golhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Welzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"1","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12969-021-00521-5","volume":"19","author":"DM d\u2019Angelo","year":"2021","unstructured":"d\u2019Angelo DM, Di Donato G, Breda L, Chiarelli F. Growth and puberty in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021;19(1):28.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1184_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1546-0096-8-20","volume":"8","author":"LN Moorthy","year":"2010","unstructured":"Moorthy LN, Peterson MG, Hassett AL, Lehman TJ. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12969-017-0189-6","volume":"15","author":"ES Sen","year":"2017","unstructured":"Sen ES, Morgan MJ, MacLeod R, Strike H, Hinchcliffe A, Dick AD, et al. Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2017;15(1):58.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1093\/rheumatology\/keab079","volume":"60","author":"K Oen","year":"2021","unstructured":"Oen K, Tian J, Loughin TM, Shiff NJ, Tucker LB, Huber AM, et al. Causal pathways to health-related quality of life in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Rheumatology (Oxford). 2021;60(10):4691\u2013702.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1093\/rheumatology\/keaa118","volume":"59","author":"A Chhabra","year":"2020","unstructured":"Chhabra A, Robinson C, Houghton K, Cabral DA, Morishita K, Tucker LB, et al. Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience. Rheumatology (Oxford). 2020;59(12):3727\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1184_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/BOR.0000000000000723","volume":"32","author":"I Maccora","year":"2020","unstructured":"Maccora I, Sen ES, Ramanan AV. Update on noninfectious uveitis in children and its treatment. Curr Opin Rheumatol. 2020;32(5):395\u2013402.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"1184_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/cts.12760","volume":"13","author":"S Paul","year":"2020","unstructured":"Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, et al. Exposure-response relationship of certolizumab pegol and achievement of low disease activity and remission in patients with rheumatoid arthritis. Clin Transl Sci. 2020;13(4):743\u201351.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40262-018-0680-3","volume":"58","author":"D Ternant","year":"2019","unstructured":"Ternant D, Azzopardi N, Raoul W, Bejan-Angoulvant T, Paintaud G. Influence of antigen mass on the pharmacokinetics of therapeutic antibodies in humans. Clin Pharmacokinet. 2019;58(2):169\u201387.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ l\u2019Ami","year":"2018","unstructured":"l\u2019Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, van der Nurmohamed MT, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-023-00930-8","volume":"22","author":"T Welzel","year":"2024","unstructured":"Welzel T, Golhen K, Atkinson A, Gotta V, Ternant D, Kuemmerle-Deschner JB, et al. Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases. Pediatr Rheumatol Online J. 2024;22(1):5.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1184_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12969-021-00495-4","volume":"19","author":"K Sorensen","year":"2021","unstructured":"Sorensen K, Skirbekk H, Kvarstein G, Woien H. I don\u2019t want to think about it: a qualitative study of children (6\u201318 years) with rheumatic diseases and parents\u2019 experiences with regular needle injections at home. Pediatr Rheumatol Online J. 2021;19(1):8.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13075-020-02165-4","volume":"22","author":"S Dierckx","year":"2020","unstructured":"Dierckx S, Sokolova T, Lauwerys BR, Avramovska A, de Bellefon LM, Toukap AN, et al. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA cohort. Arthritis Res Ther. 2020;22(1):96.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1184_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/rheumatology\/keab354","volume":"61","author":"MJH Doeleman","year":"2021","unstructured":"Doeleman MJH, de Roock S, El Amrani M, van Maarseveen EM, Wulffraat NM, Swart JF. Association of adalimumab trough concentrations and treatment response in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;61(1):377\u201382.","journal-title":"Rheumatology (Oxford)"},{"key":"1184_CR16","doi-asserted-by":"crossref","unstructured":"Krieckaert C, Hernandez-Breijo B, Gehin JE, le Meledo G, Balsa A, Jani M et al. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 2022;8(2).","DOI":"10.1136\/rmdopen-2022-002216"},{"issue":"12","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1136\/annrheumdis-2014-205554","volume":"73","author":"EH Vogelzang","year":"2014","unstructured":"Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12):2178\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","volume":"139","author":"N Wilkinson","year":"2019","unstructured":"Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study. J Invest Dermatol. 2019;139(1):115\u201323.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1184_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","volume":"142","author":"G n der Kraaij","year":"2022","unstructured":"n der Kraaij G, van den Busard C, Menting S, Musters A, Hutten B, et al. Adalimumab with methotrexate vs. Adalimumab monotherapy in psoriasis: First-Year results of a Single-Blind randomized controlled trial. J Invest Dermatol. 2022;142(9):2375\u201383. e6.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"e2451341","DOI":"10.1001\/jamanetworkopen.2024.51341","volume":"7","author":"J Fan","year":"2024","unstructured":"Fan J, Hao J, Fu Y, Liu X, Qu HQ, Glessner JT, et al. Genetic association of juvenile idiopathic arthritis with adult rheumatic disease. JAMA Netw Open. 2024;7(12):e2451341.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1184_CR21","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1136\/ard-2024-225851","volume":"83","author":"B Fautrel","year":"2024","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Anton J, Belot A, et al. EULAR\/PReS recommendations for the diagnosis and management of still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1184_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u201369.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/rheumatology\/kead490","volume":"63","author":"C Triaille","year":"2024","unstructured":"Triaille C, Quartier P, De Somer L, Durez P, Lauwerys BR, Verschueren P, et al. Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis. Rheumatology (Oxford). 2024;63(3):594\u2013607.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1184_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD, Review. Genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70(1):7\u201317.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1184_CR25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/03009742.2019.1585940","volume":"48","author":"MK Meyer","year":"2019","unstructured":"Meyer MK, Andersen M, Ring T, Andersen GN, Ehlers LH, Rasmussen C, et al. Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment - a retrospective intervention analysis. Scand J Rheumatol. 2019;48(5):398\u2013407.","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"1184_CR26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40744-021-00345-5","volume":"8","author":"C Gomez-Arango","year":"2021","unstructured":"Gomez-Arango C, Gorostiza I, Ucar E, Garcia-Vivar ML, Perez CE, De Dios JR, et al. Cost-Effectiveness of therapeutic drug Monitoring-Guided adalimumab therapy in rheumatic diseases: A Prospective, pragmatic trial. Rheumatol Ther. 2021;8(3):1323\u201339.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"1184_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/rheumatology\/keae103","volume":"64","author":"CJT n der Togt","year":"2025","unstructured":"n der Togt CJT, den Broeder N, van der Boonstra MS, den Broeder AA, van Herwaarden N. Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. Rheumatology (Oxford). 2025;64(2):533\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1184_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-022-02751-8","volume":"24","author":"MS n der Leeuw","year":"2022","unstructured":"n der Leeuw MS, Messelink MA, Tekstra J, Medina O, van Laar JM, Haitjema S, et al. Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions. Arthritis Res Ther. 2022;24(1):74.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00228-020-02925-w","volume":"76","author":"C Bastida","year":"2020","unstructured":"Bastida C, Huitema ADR, l\u2019Ami MJ, Ruiz-Esquide V, Wolbink GJ, Sanmarti R, et al. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic\/pharmacodynamic simulations. Eur J Clin Pharmacol. 2020;76(10):1417\u201325.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1184_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3899\/jrheum.161078","volume":"44","author":"DB Horton","year":"2017","unstructured":"Horton DB, Onel KB, Beukelman T, Ringold S. Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: a survey of the childhood arthritis and rheumatology research alliance. J Rheumatol. 2017;44(3):352\u201360.","journal-title":"J Rheumatol"},{"issue":"2","key":"1184_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/kez285","volume":"59","author":"RHJ Verstegen","year":"2020","unstructured":"Verstegen RHJ, McMillan R, Feldman BM, Ito S, Laxer RM. Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review. Rheumatology (Oxford). 2020;59(2):386\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"1184_CR32","doi-asserted-by":"crossref","unstructured":"Golhen K, Welzel T, Atkinson A, Koch G, van den Braem D et al. Influence of disease type and activity on adalimumab exposure in children with inflammatory rheumatic diseases. J Clin Pharmacol. 2025.","DOI":"10.1002\/jcph.70045"},{"issue":"1","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10957-021-01819-w","volume":"189","author":"F Bachmann","year":"2021","unstructured":"Bachmann F, Koch G, Pfister M, Szinnai G, Schropp J. OptiDose: computing the individualized optimal drug dosing regimen using optimal control. J Optim Theory Appl. 2021;189(1):46\u201365.","journal-title":"J Optim Theory Appl"},{"issue":"3","key":"1184_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10928-022-09840-w","volume":"50","author":"F Bachmann","year":"2023","unstructured":"Bachmann F, Koch G, Bauer RJ, Steffens B, Szinnai G, Pfister M, et al. Computing optimal drug dosing with optidose: implementation in NONMEM. J Pharmacokinet Pharmacodyn. 2023;50(3):173\u201388.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1184_CR35","doi-asserted-by":"crossref","unstructured":"Bram D, Bachmann F, Schropp J, Gotta V, van den Steffens B et al. Understanding and streamlining dose finding: from dose simulation to dose Estimation. J Clin Pharmacol. 2025.","DOI":"10.1002\/jcph.6188"},{"issue":"4","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40272-024-00629-7","volume":"26","author":"A Nassar-Sheikh Rashid","year":"2024","unstructured":"Nassar-Sheikh Rashid A, Hooijberg F, Bergkamp SC, Gruppen MP, Kuijpers TW, Nurmohamed M, et al. Population pharmacokinetics of adalimumab in juvenile idiopathic arthritis patients: A retrospective cohort study using clinical care data. Paediatr Drugs. 2024;26(4):441\u201350.","journal-title":"Paediatr Drugs"},{"issue":"7","key":"1184_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00296-022-05108-1","volume":"42","author":"A Garcia-Fernandez","year":"2022","unstructured":"Garcia-Fernandez A, Briones-Figueroa A, Calvo-Sanz L, Andreu-Suarez A, Boteanu A. Evaluation of flare rate and reduction strategies for bDMARDs in juvenile idiopathic arthritis: real world data from a single-centre cohort. Rheumatol Int. 2022;42(7):1133\u201342.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keac463","volume":"62","author":"L Kearsley-Fleet","year":"2023","unstructured":"Kearsley-Fleet L, Baildam E, Beresford MW, Douglas S, Foster HE, Southwood TR, et al. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis. Rheumatology (Oxford). 2023;62(5):1926\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1184_CR39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.41488","volume":"73","author":"P Quartier","year":"2021","unstructured":"Quartier P, Alexeeva E, Constantin T, Chasnyk V, Wulffraat N, Palmblad K, et al. Tapering Canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb\/IV Open-Label, randomized study. Arthritis Rheumatol. 2021;73(2):336\u201346.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12969-022-00725-3","volume":"20","author":"T Welzel","year":"2022","unstructured":"Welzel T, Oefelein L, Twilt M, Pfister M, Kuemmerle-Deschner JB, Benseler SM. Tapering of biological treatment in autoinflammatory diseases: a scoping review. Pediatr Rheumatol Online J. 2022;20(1):67.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"8","key":"1184_CR41","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s10067-023-06616-6","volume":"42","author":"GR Currie","year":"2023","unstructured":"Currie GR, Groothuis-Oudshoorn CGM, Twilt M, Kip MMA, MJ IJ, Benseler SM, et al. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey. Clin Rheumatol. 2023;42(8):2173\u201380.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","volume":"21","author":"O Halyabar","year":"2019","unstructured":"Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs. 2019;21(6):469\u201392.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12969-024-01046-3","volume":"22","author":"E Balay-Dustrude","year":"2024","unstructured":"Balay-Dustrude E, Fennell J, Baszis K, Goh YI, Horton DB, Lee T, et al. Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review. Pediatr Rheumatol Online J. 2024;22(1):112.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-019-0342-5","volume":"17","author":"S Shenoi","year":"2019","unstructured":"Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, et al. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, childhood arthritis and rheumatology research alliance (CARRA) survey. Pediatr Rheumatol Online J. 2019;17(1):48.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"1184_CR45","first-page":"1349","volume":"32","author":"N Saxena","year":"2005","unstructured":"Saxena N, Aggarwal A, Misra R. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol. 2005;32(7):1349\u201353.","journal-title":"J Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01184-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01184-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:04:00Z","timestamp":1771434240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01184-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01184-w","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This simulation study was performed in a pharmacometric simulation framework with virtual patients without real patients` data, therefore ethics committee approval and informed consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}